Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.58 |
| ▸ | KIF11 | P52732 | 2/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | TGM2 | P21980 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3973745 | 0.81 | ALDH1A1 (0.55) | RAB9ATGM2NPC1MAPTALDH1A1 | |
| SCHEMBL4099319 | 0.80 | KIF11 (0.63) | EPHX2KIF11PTGS1RAB9ATGM2 | |
| SCHEMBL3969793 | 0.77 | NPC1 (0.55) | EPHX2RAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL3723958 | 0.77 | NAPRT (0.52) | EPHX2RAB9ATGM2NPC1MAPT | |
| Bicarbonate SCHEMBL2945476 | 0.76 | KIF11 (0.62) | EPHX2KIF11PTGS1RAB9ATGM2 | |
| SCHEMBL4099321 | 0.76 | KIF11 (0.53) | EPHX2KIF11PTGS1RAB9ATGM2 | |
| SCHEMBL27214948 | 0.75 | RAB9A (0.61) | EPHX2KIF11PTGS1RAB9ATGM2 | |
| SCHEMBL23328672 | 0.75 | EPHX2 (0.51) | EPHX2KIF11RAB9ATGM2NPC1 | |
| SCHEMBL3975948 | 0.75 | NPC1 (0.59) | RAB9ATGM2NPC1MAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL16701795 | 0.75 | KIF11 (0.51) | EPHX2KIF11PTGS1RAB9ATGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759357-B2 | Phenylpyrimidine amines as IgE inhibitors | NOVARTIS AG (CH) | 2010-07-20 | — | — | US | disclosed |
| CN-101684097-A | Phenylpyrimidine amines as ige inhibitors | NOVARTIS AG | 2010-03-31 | — | — | CN | disclosed |
| EP-1474146-B1 | PHENYLPYRIMIDINE AMINES AS IGE INHIBITORS | NOVARTIS AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20070281956-A1 | Phenylpyrimidine amines as IgE inhibitors | NOVARTIS AG (CH) | 2007-12-06 | — | — | US | disclosed |
| US-20050119255-A1 | Phenylpyrimidine amines as ige inhibitors | BULUSU MURTY (AT) | 2005-06-02 | — | — | US | disclosed |
| CN-1622807-A | Phenyl pyrimidine substituted amines as IgE inhibitors | NOVARTIS AG (CH) | 2005-06-01 | — | — | CN | disclosed |
| EP-1474146-A1 | PHENYLPYRIMIDINE AMINES AS IGE INHIBITORS | Novartis AG (CH) | 2004-11-10 | — | — | EP | disclosed |
| WO-2003063871-A1 | PHENYLPYRIMIDINE AMINES AS IGE INHIBITORS | NOVARTIS AG (CH) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281956-A1 | Phenylpyrimidine amines as IgE inhibitors | FCER2, SELP, FCGR2A | EPHX2 311/4885KIF11 4521/4885PTGS1 1713/4885 |
| US-20050119255-A1 | Phenylpyrimidine amines as ige inhibitors | FCER2, SELP, FCGR2A | EPHX2 311/4885KIF11 4521/4885PTGS1 1713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.